FDA Approves First Oral Therapy for Covid-19 Prevention
The FDA has approved Shionogi’s Xocova (ensitrelvir) as the first oral therapy for post-exposure prophylaxis of Covid-19 in adults and adolescents aged 12 and older. Clinical trials showed a 67% reduction in symptomatic Covid-19 cases through Day 10 compared to placebo. This approval expands the role of antiviral treatments to include prevention.
The U.S. Food and Drug Administration (FDA) has approved Shionogi’s Xocova (ensitrelvir), representing a significant advancement in Covid-19 prevention. This approval makes Xocova the first and only oral therapy available for post-exposure prophylaxis in adults and adolescents aged 12 years and older. The decision was informed by clinical data showing that Xocova reduces the risk of developing symptomatic Covid-19 by 67% through Day 10 compared to a placebo. This is a pivotal moment in the fight against Covid-19, as it broadens the role of antiviral therapies from treatment to include preventative measures, potentially changing the landscape of public health strategies.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Liam covers climate solutions and the people helping the planet heal.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
